Wednesday, June 19, 2019  | 15 Shawwal, 1440 | BETA
Samaa TV
Facebook Twitter Youtube
HOME > Economy

Pfizer third-quarter profit beats estimates; oncology drugs shine

October 29, 2013
Pfizer third-quarter profit beats estimates; oncology drugs shine

NEW YORK: Pfizer Inc reported better-than-expected third-quarter earnings on Tuesday, helped by costs cuts and growing sales of recently approved cancer medicines.The largest U.S. drugmaker said it earned $2.59 billion, or 39 cents per share in the quarter, compared with $3.21 billion, or 43 cents per share, in the year-earlier period.Excluding special items, Pfizer earned 58 cents per share. Analysts, on average, expected 56 cents per share, according to Thomson Reuters I/B/E/S.Global company sales fell 2 percent to $12.64 billion, hurt by generic competition for cholesterol fighter Lipitor and other medicines. Wall Street had expected sales of $12.7 billion.Sales of its oncology drugs jumped 24 percent in the quarter to $407 million, in contrast to declining sales of Pfizer's array of specialty care and primary care medicines.Its shares were little changed in premarket trading..–REUTERS

 
 
RELATED STORIES
 

Tell us what you think:

Your email address will not be published.

 
 
 
 
 
 
 
MOST READ